What is Cell Microsystems?
Cell Microsystems develops sophisticated tools for imaging, sorting, and isolating individual cells and colonies, serving vital research sectors including CRISPR gene editing, cancer research, and stem cell biology. Their innovative product suite, featuring systems like the CellRaft AIR System for enhanced clonal outgrowth, alongside solutions for 3D cell culture and automated cell counting, empowers researchers in prominent institutions and pharmaceutical companies. By enabling high-throughput cellular analysis and isolation, Cell Microsystems is instrumental in driving advancements across diverse biological fields.
How much funding has Cell Microsystems raised?
Cell Microsystems has raised a total of $14.6M across 4 funding rounds:
Grant
$1.5M
Debt
$150K
Debt
$292K
Other Financing Round
$12.7M
Grant (2018): $1.5M, investors not publicly disclosed
Debt (2020): $150K led by PPP
Debt (2021): $292K supported by PPP
Other Financing Round (2021): $12.7M featuring Telegraph Hill Partners
Key Investors in Cell Microsystems
Telegraph Hill Partners
Telegraph Hill Partners is a venture capital firm established in 2001, specializing in investments in commercial-stage life science, medical technology, and healthcare companies.
PPP
Public-Private Partnership
What's next for Cell Microsystems?
With the recent major enterprise-level funding, Cell Microsystems is strategically positioned for accelerated scaling and product development. The company's focus on enabling high-throughput cellular analysis and isolation suggests a trajectory towards expanding its market reach within the life sciences and biotechnology sectors. Future investments will likely be directed towards enhancing their technological capabilities, broadening their customer base, and potentially exploring new applications for their advanced cell isolation and imaging platforms, reinforcing their role in cutting-edge biological research.
See full Cell Microsystems company page
